1. Absolute change in HbA1c levels in the muraglitazar and pioglitazone study arms at week 24
End point
Muraglitazar 5 mg plus metformin (n=569)
Pioglitazone 30 mg plus metformin (n=550)
HbA1c difference between study arms p
Change in HbA1c levels (%)
-1.14
-0.85
0.29
<0.0001
Kendall D. American Diabetes Association 2005 Scientific Sessions; June 10-14, 2005; San Diego, CA.

2. Relative change in lipid parameters from baseline in the muraglitazar and pioglitazone study arms at week 12
End point
Muraglitazar 5 mg plus metformin (n=569)
Pioglitazone 30 mg plus metformin (n=550) p
Change in triglyceride levels (%)
-28.4
-13.4
<0.0001
Change in HDL cholesterol levels (%)
19.2
13.6
Change in apolipoprotein B levels (%)
-11.8
-6.0
Change in non-HDL cholesterol levels (%)
-5.9
-1.2
Kendall D. American Diabetes Association 2005 Scientific Sessions; June 10-14, 2005; San Diego, CA.